BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37331346)

  • 1. Diagnostic Utility of Claudin4 and Comparison with BerEp4 as a Marker for Metastatic Adenocarcinoma in Serous Effusions.
    Mangla G; Bakshi P; Agarwal P; Verma K
    Acta Cytol; 2023; 67(5):564-572. PubMed ID: 37331346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.
    Patel A; Borczuk AC; Siddiqui MT
    J Am Soc Cytopathol; 2020; 9(3):146-151. PubMed ID: 32184064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refined Diagnosis of Pleural Effusions by Immunocytochemistry of Cell Blocks.
    Koyi H; Wilander E
    Anticancer Res; 2023 Feb; 43(2):669-673. PubMed ID: 36697096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Metastatic Carcinoma Using Body Cavity Fluid Specimens: A Comparison of Diagnostic Panels.
    Sridakhun N; Intarawichian P; Thanee M; Watcharadetwittaya S
    Acta Cytol; 2023; 67(3):257-264. PubMed ID: 36513033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
    Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
    Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2, a unique marker of malignancy in effusion cytology.
    Jiang H; Gupta R; Somma J
    Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study.
    Hruaii V; Thirunavukkarasu B; Prabha V; Mathur S; Iyer VK; Nambirajan A; Jain D
    Diagn Cytopathol; 2024 Jan; 52(1):30-41. PubMed ID: 37837242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
    Jo VY; Cibas ES; Pinkus GS
    Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of Claudin-4 and EZH2 Immunohistochemistry in Effusion Cytology.
    Elhosainy A; Hafez MMA; Yassin EH; Adam M; Elnaggar MS; Aboulhagag NA
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2779-2785. PubMed ID: 36037134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
    Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens.
    Najjar S; Gan Q; Stewart J; Sneige N
    Cancer Cytopathol; 2023 Apr; 131(4):245-253. PubMed ID: 36522809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Accuracy of Cell Block and Immunohistochemistry in Effusion Cytology.
    Batool S; Sadaf S; Chughtai AS; Qasim A; Zafar A; Jamil A
    Cureus; 2023 Feb; 15(2):e34958. PubMed ID: 36938247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology.
    Patil B; Shivkumar V; Gangane N
    Indian J Pathol Microbiol; 2018; 61(1):90-93. PubMed ID: 29567891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens.
    Vojtek M; Walsh MD; Papadimos DJ; Shield PW
    Cytopathology; 2019 Nov; 30(6):614-619. PubMed ID: 31390089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.